ADRB2 and AL amyloidosis: There are methods for the ex vivo expansion and adoptive transfer of Vδ1+ cells has been used in the treatment of multiple myeloma (41), colon cancer (42), B-cell chronic lymphocytic leukemia (43), and glioblastoma (44), but it remains to be seen if systemic β-AR activation can augment the ex vivo manufacture of this cell type also.